Receptor-binding autoantibodies are not associated with post-COVID fatigue
4 affiliations
- 1Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- 2Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- 3Division of Infectious Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
- 4Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Corresponding author. Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Abstract
Persistent fatigue is a common symptom following SARS-CoV-2 infection, but its underlying mechanisms remain incompletely understood. Autoantibodies targeting G-protein coupled receptors and other neurotransmitter-related receptors have been proposed as potential biomarkers or mediators of post-COVID symptoms. However, their association with post-COVID fatigue remains unclear. Therefore, in the current study, we investigated receptor-binding autoantibodies against 13 neurotransmitter-related receptors in 206 participants with prior infection with SARS-CoV-2. Three groups of patients were enrolled: controls with no persistent fatigue, patients experiencing new-onset post-infection fatigue, and a group of patients who already suffered from fatigue before their infection with SARS-CoV-2. Fatigue was assessed using a standardized self-reported fatigue questionnaire. We found no significant differences in the concentrations of the measured receptor-binding autoantibodies between participants with new-onset fatigue, pre-existing fatigue, and controls without persistent fatigue. In multivariable analyses, none of the individual antibody concentrations was significantly associated with new-onset fatigue after adjustment for age, sex, and time since infection and correction for multiple testing. Individual antibody concentrations were also not associated with fatigue severity. The proportion of participants exceeding manufacturer-defined reference values did not differ significantly between the study groups. Similarly, cumulative antibody positivity was not associated with fatigue severity. In conclusion, in this cohort of SARS-CoV-2-infected participants, we found no evidence that concentrations of the measured receptor-binding autoantibodies are associated with post-COVID fatigue or fatigue severity. These findings do not support the use of these antibodies as stand-alone biomarkers of post-COVID fatigue. Because all participants had previously experienced SARS-CoV-2 infection, the study cannot determine whether infection itself alters antibody concentrations. Furthermore, the binding assays do not establish whether the detected antibodies have functional receptor activity. These findings underscore the urgent need for longitudinal studies with comprehensive clinical phenotyping and functional antibody assays are needed to further investigate the potential role of receptor-binding autoantibodies in post-COVID symptoms.
Related
- Fibromyalgia, Chronic Fatigue Syndrome, and Multiple Sclerosis are associated with lower translocator protein binding affinity genotypes
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies
- The Context of Recovery Among Adults Who Recover from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post-COVID Condition Following Mind-Body Approaches: A Qualitative Descriptive Study Protocol
- Long COVID burden in primary care: quality of life, fatigue, sleep and function
- N-Glycosylation in the Receptor Binding Domain serves as aggregation gatekeeper of the SARS CoV2 Spike glycoprotein folding
BibTeX
@article{achleitner2026receptorbinding,
title = {{Receptor-binding autoantibodies are not associated with post-COVID fatigue}},
author = {Martin Achleitner and Juliane Dänhardt and Romina Kardashi and Nicole Toepfner and Katja de With and Zhenfei Li and Natalia Jarzebska and Roman N. Rodionov and Stefan R. Bornstein and Charlotte Steenblock},
journal = {Brain, Behavior, \& Immunity - Health},
year = {2026},
month = oct,
doi = {10.1016/j.bbih.2026.101393},
url = {https://doi.org/10.1016/j.bbih.2026.101393},
note = {CC BY},
}
RIS
TY - JOUR
TI - Receptor-binding autoantibodies are not associated with post-COVID fatigue
AU - Martin Achleitner
AU - Juliane Dänhardt
AU - Romina Kardashi
AU - Nicole Toepfner
AU - Katja de With
AU - Zhenfei Li
AU - Natalia Jarzebska
AU - Roman N. Rodionov
AU - Stefan R. Bornstein
AU - Charlotte Steenblock
PY - 2026
DA - 2026/10/23
JO - Brain, Behavior, & Immunity - Health
DO - 10.1016/j.bbih.2026.101393
UR - https://doi.org/10.1016/j.bbih.2026.101393
AB - Persistent fatigue is a common symptom following SARS-CoV-2 infection, but its underlying mechanisms remain incompletely understood. Autoantibodies targeting G-protein coupled receptors and other neurotransmitter-related receptors have been proposed as potential biomarkers or mediators of post-COVID symptoms. However, their association with post-COVID fatigue remains unclear. Therefore, in the current study, we investigated receptor-binding autoantibodies against 13 neurotransmitter-related receptors in 206 participants with prior infection with SARS-CoV-2. Three groups of patients were enrolled: controls with no persistent fatigue, patients experiencing new-onset post-infection fatigue, and a group of patients who already suffered from fatigue before their infection with SARS-CoV-2. Fatigue was assessed using a standardized self-reported fatigue questionnaire. We found no significant differences in the concentrations of the measured receptor-binding autoantibodies between participants with new-onset fatigue, pre-existing fatigue, and controls without persistent fatigue. In multivariable analyses, none of the individual antibody concentrations was significantly associated with new-onset fatigue after adjustment for age, sex, and time since infection and correction for multiple testing. Individual antibody concentrations were also not associated with fatigue severity. The proportion of participants exceeding manufacturer-defined reference values did not differ significantly between the study groups. Similarly, cumulative antibody positivity was not associated with fatigue severity. In conclusion, in this cohort of SARS-CoV-2-infected participants, we found no evidence that concentrations of the measured receptor-binding autoantibodies are associated with post-COVID fatigue or fatigue severity. These findings do not support the use of these antibodies as stand-alone biomarkers of post-COVID fatigue. Because all participants had previously experienced SARS-CoV-2 infection, the study cannot determine whether infection itself alters antibody concentrations. Furthermore, the binding assays do not establish whether the detected antibodies have functional receptor activity. These findings underscore the urgent need for longitudinal studies with comprehensive clinical phenotyping and functional antibody assays are needed to further investigate the potential role of receptor-binding autoantibodies in post-COVID symptoms.
SN - 2666-3546
ER -